GlassScriptPhysician profile
Graham M Woolf
NPI 1336282094
$10,547.70
in general payments reported to CMS, 2019-2025
32 companies · $449 in 2025
The $449 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,439 · 2020: $1,742 · 2021: $1,766 · 2022: $2,129 · 2023: $1,240 · 2024: $783 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,432 · Education: $38.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,432.46 |
| Education | $38.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,740.01 | 2019-2025 | Skyrizi, Linzess, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,817.18 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,217.14 | 2019-2025 | Entyvio, Gattex |
| Gilead Sciences, INC. | $1,023.00 | 2019-2024 | |
| Janssen Biotech, INC. | $880.30 | 2019-2025 | Stelara, Tremfya, Simponi |
| Daiichi Sankyo INC. | $332.77 | 2019-2022 | |
| Pfizer INC. | $313.57 | 2019-2025 | |
| Qol Medical, LLC | $268.20 | 2021-2025 | Sucraid |
| Celgene Corporation | $253.70 | 2021-2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $248.01 | 2019-2024 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $184.80 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $155.61 | 2019-2024 | |
| Edwards Lifesciences Corporation | $117.57 | 2024-2025 | Sapien 3 Ultra Resilia |
| Ardelyx, INC. | $106.61 | 2022 | |
| Nestle Healthcare Nutrition INC. | $105.32 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $86.65 | 2022-2024 | |
| Redhill Biopharma INC. | $80.78 | 2020-2021 | |
| Mirum Pharmaceuticals, INC. | $76.84 | 2023-2025 | Livmarli |
| Braintree Laboratories, INC. | $75.54 | 2019-2021 | |
| Romark Laboratories, Lc | $70.34 | 2019 | |
| Ferring Pharmaceuticals INC. | $64.68 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $47.36 | 2023 | Dupixent |
| Alfasigma USA, INC. | $46.42 | 2020-2021 | |
| Allergan, INC. | $39.80 | 2019 | |
| Amgen INC. | $34.78 | 2022 | |
| Shionogi INC | $26.88 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $25.59 | 2024 | |
| Novo Nordisk INC | $25.35 | 2024 | Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $23.05 | 2025 | |
| Phathom Pharmaceuticals, INC. | $21.34 | 2025 | Voquezna |
| Concordia Pharmaceuticals INC. | $20.00 | 2019 | |
| Boston Scientific Corporation | $18.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Graham Woolf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.